Patent · US Active

Indazolones as modulators of TNF signaling

US10273238B2 · kind B2 · utility

0Cited by

3References

22Claims

0Family size

Assignee

Abb Vie Inc. · US

Inventors

Eric C. Breinlinger · Charlton, US
Andrew Burchat · Shrewsbury, US
Justin D. Dietrich · Libertyville, US
Michael Friedman · Jerusalem, IL
David C. Ihle · Worcester, US
David Kinsman · Worcester, US
Kelly D. Mullen · Charlton, US
Augustine Osuma · Lindenhurst, US
Anil Vasudevan · Union Grove, US
Noel S. Wilson · Kenosha, US

Key dates

Filing date	Dec 22, 2017
Grant date	Apr 30, 2019
Priority date	—
Expiry date	Dec 22, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.